BPC-157 is a peptide composed of 15 amino acids, in a sequence of: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val BPC-157 has enhanced stability compared to other peptides, and is one of the only peptides that is available to be taken as an oral supplement
Patient Profile: 40-year-old female presenting with: Morbid obesity Newly diagnosed Type 2 Diabetes Mellitus Mixed dyslipidemia MASLD Positive history of gestational diabetes Strong family history of Type 2 Diabetes & cardiovascular disease Baseline Clinical Status: Weight: 96 kg HbA1c: 9.8% Random Blood Glucose: 380 mg/dL Blood Pressure: 130/85 mmHg LDL-C: 188 mg/dL Triglycerides: 396 mg/dL Liver Enzymes: Elevated ALT: 65 U/L AST: 46 U/L GGT: 93 U/L Comprehensive Treatment Strategy: Intensive lifestyle modification Empagliflozin + Metformin XR (25/1000 mg) Rosuvastatin + Ezetimibe (10/10 mg) Therapeutic Escalation Tirzatrim (Tirzepatide) was introduced 4.5 months ago, initiated at 2.5 mg once weekly and gradually titrated to 7.5 mg once weekly, while continuing background cardiometabolic therapy
Am J Med 2009;122:778 e1-7
Our goal is to provide insights into the prospective development and clinical application of novel AD drugs
Non-Invasive : No surgery, recovery time, or major lifestyle disruptions required
Fatigue, headache, or mild dizziness may also occur, particularly during the early stages of therapy
